Literature DB >> 1986724

The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis.

J T Kissel1, R K Halterman, K W Rammohan, J R Mendell.   

Abstract

Accumulating evidence indicates that a complement-mediated microvasculopathy may play a pathogenic role in dermatomyositis. In a previous study, we demonstrated neoantigens of the C5b-9 complement membrane attack complex in the muscle microvasculature of childhood and adult cases of dermatomyositis. To further characterize the relationship between the vascular complement deposits and histologic changes, quantitative histopathologic analyses were performed on 39 dermatomyositis biopsy specimens (26 adult, 13 children). There was a significant correlation between the percentage of fascicles with fibers having focal myofibrillar loss, a change seen early in the evolution of ischemic muscle fiber damage, and the percentage of fascicles having capillary deposits of membrane attack complex. Conversely, in biopsy specimens with a higher percentage of fascicles with perifascicular atrophy, membrane attack complex deposits were significantly less common. A fascicle-by-fascicle analysis supported these observations. Patients whose biopsy specimens were negative for microvascular membrane attack complex had clinical weakness for a significantly longer time than those patients with vascular complement deposits. These data support the hypothesis that the complement-mediated vasculopathy is a primary immunopathogenic event in the evolution of muscle lesions in dermatomyositis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1986724     DOI: 10.1001/archneur.1991.00530130034016

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  24 in total

1.  Complement activation promotes muscle inflammation during modified muscle use.

Authors:  J Frenette; B Cai; J G Tidball
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Complement neoantigen and vitronectin are components of plaques in amyloid AL neuropathy.

Authors:  G L Zanusso; G Moretto; B Bonetti; S Monaco; N Rizzuto
Journal:  Ital J Neurol Sci       Date:  1992-09

3.  Mitochondrial abnormalities in dermatomyositis: characteristic pattern of neuropathology.

Authors:  Mohammed I Alhatou; John T Sladky; Omar Bagasra; Jonathan D Glass
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

4.  Inflammatory myopathies.

Authors:  B Jane Distad; Anthony A Amato; Michael D Weiss
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

5.  Myopathy with antibodies to the signal recognition particle: clinical and pathological features.

Authors:  T Miller; M T Al-Lozi; G Lopate; A Pestronk
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

6.  Preferential infiltration of interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis.

Authors:  T Fujiyama; T Ito; N Ogawa; T Suda; Y Tokura; H Hashizume
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

7.  Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases.

Authors:  A Sansome; V Dubowitz
Journal:  Arch Dis Child       Date:  1995-01       Impact factor: 3.791

8.  Dermatomyositis and Polymyositis.

Authors:  Hannah R. Briemberg; Anthony A. Amato
Journal:  Curr Treat Options Neurol       Date:  2003-09       Impact factor: 3.598

9.  MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies.

Authors:  E Bartoccioni; S Gallucci; F Scuderi; E Ricci; S Servidei; A Broccolini; P Tonali
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

10.  Differential immunohistological features of inflammatory myopathies and dysferlinopathy.

Authors:  Jae-Hwan Choi; Yeong-Eun Park; Sung-Il Kim; Jeong-Il Kim; Chang-Hoon Lee; Kyu-Hyun Park; Dae-Seong Kim
Journal:  J Korean Med Sci       Date:  2009-11-07       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.